New drug combo for leukemia after prior treatment fails
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs for people with acute myeloid leukemia (AML) whose cancer did not respond to or stopped responding to the usual first-line treatment. The goal is to see if this new approach can help where the previous one didn't.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acute myeloid leukemia (AML), but not a rare subtype called acute promyelocytic leukemia (APL).
- Your previous treatment with venetoclax plus azacitidine either caused severe side effects or did not work well enough (cancer did not go away, came back, or genetic markers increased).
- You are in generally good health (able to do light activity) and your heart, liver, and kidneys are working well enough.
- You do not have active infections (like HIV, hepatitis B or C), severe heart problems, or other uncontrolled cancers.
- If you are pregnant or breastfeeding, you cannot join, and if you could become pregnant, you must use effective birth control during the study and for 6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (venetoclax, homoharringtonine, and azacitidine) plus a growth factor to treat newly diagnosed AML in people who aren't strong enough for standard chemo. The goal is to see if this combo can help control the leukemia with fewer side effects.
This trial tests a combination of three drugs—homoharringtonine, lisaftoclax, and azacitidine—for people with acute myeloid leukemia (AML) whose cancer did not respond to or has returned after prior treatment with venetoclax. The goal is to see if this new combination can help control the leukemia when current options have failed.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This trial tests a combination of three chemotherapy drugs (venetoclax, azacitidine, and cytarabine) for people newly diagnosed with acute myeloid leukemia who have never received AML treatment before. The goal is to see if this combination can help patients go into remission and live longer.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
This trial tests a new drug combination (venetoclax plus CACAG chemotherapy) for people whose acute myeloid leukemia has come back or not responded to earlier treatments. The goal is to see if this combination can help control the leukemia.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.